News | Cardiovascular Surgery | May 03, 2019

Open Heart Surgery Outperforms Stents in Patients With Multivessel Disease

Study reinforces value of heart team approach when making treatment decisions

Open Heart Surgery Outperforms Stents in Patients With Multivessel Disease

May 3, 2019 — Coronary artery bypass grafting (CABG) surgery may be the best treatment option for most patients with more than one blocked heart artery, according to research published online in The Annals of Thoracic Surgery.1

“Our data demonstrate a significant mortality benefit with CABG over percutaneous coronary intervention (PCI), and this benefit is consistent across virtually all major patient groups, suggesting that CABG should be considered in broader patient populations, not just in cases of patients with diabetes and left ventricular dysfunction, which is what is commonly practiced,” said lead author Suresh R. Mulukutla, M.D., from the University of Pittsburgh Medical Center (UPMC) in Pennsylvania.

Mulukutla and colleagues examined data from two major clinical outcomes registries for heart patients — The Society of Thoracic Surgeons (STS) National Database and the American College of Cardiology Foundation National Cardiovascular Data Registry (NCDR). The researchers identified patients with multivessel coronary artery disease who underwent CABG or PCI between 2010 and 2018 at UPMC. Those who met the eligibility criteria were separated into two groups — CABG and PCI — each including 844 patients. The analyses focused on outcomes for mortality, readmission and revascularization.

The researchers found that the estimated one-year mortality for patients in the CABG group was 7.2 percent, as compared to 11.5 percent the PCI group. The CABG group also experienced lower risk of hospital readmission (28.1 percent vs. 38.4 percent) and revascularization (1 percent vs. 6.7 percent) than the PCI group.

“A major point in the study is the focus on the current era of revascularization with the most currently available stents,” said Mulukutla. “This research is really a modern, ‘real-world’ experience. While randomized clinical trials are clearly important, real-world analyses also can be very instructive because they provide insights on how we are making clinical decisions. For instance, the last several years have seen a shift toward more PCI over CABG. While there may be valid reasons for this, our data — which show CABG outperforming PCI in almost every patient group — should push us to further discuss all of the options.”

PCI, often referred to as angioplasty, is a nonsurgical procedure that uses a thin, flexible catheter placed into an artery in the groin or arm. A balloon on the end of the catheter is positioned in the narrowed coronary artery and inflated to open up the blockage. A stent is a metal mesh tube that is left behind to help keep the artery from collapsing. Drugs attached to the stent help prevent the body from reacting to the stent and shutting down the artery again.

CABG, the most commonly performed heart operation in the United States, is designed to bypass the blockages in the coronary arteries in order to create a new path for blood flow to the heart. The surgeon removes a healthy blood vessel, usually from the leg, arm, chest or abdomen, and connects it to the other arteries (usually the aorta) in the heart. This enables blood flow to go around the diseased or blocked portion of the coronary artery.

The decision between open heart surgery and PCI for treatment of patients with multiple narrowed arteries is not always straightforward, according to Mulukutla. Thus, these more complex treatment decisions should be made with the guidance of a heart care team.

“Both cardiac surgery and stenting have roles among patients with coronary artery disease,” said Mulukutla. “Because of this, it is important to deliberate carefully with the help of a heart team. The team can ensure that a multidisciplinary approach is used when offering recommendations to patients and assisting them in making informed decisions.”

A heart care team generally includes cardiothoracic surgeons and cardiologists. Other healthcare providers such as primary care physicians, physician assistants, nurse practitioners, imaging specialists and anesthesiologists also may be part of the team. This approach leverages the expertise of these advanced practice providers in an effort to improve the efficiency and advance the quality of care for patients.

With revascularization, heart team input is often limited because PCI can be completed at the time of a patient’s diagnostic procedure. When this happens, the physicians do not have the opportunity to discuss the spectrum of possible treatment options. As a result, the practical and consistent use of the heart team for decision-making in the treatment of patients with complex coronary artery diseases is lacking, Mulukutla explained.

“We are working to better facilitate a heart team approach and overcome some of the limitations given the current infrastructure of how these decisions are made,” said Mulukutla. “We also are continuing to identify specific patient populations that may benefit from either CABG or PCI so that we can best advocate for our patients.”

For more information: www.annalsthoracicsurgery.org

 

Reference

1. Mulukutla S.R., Gleason T.G., Sharbaugh M., et al. Coronary Bypass Versus Percutaneous Revascularization in Multivessel Coronary Artery Disease. Annals of Thoracic Surgery, published online May 1, 2019. DOI: 10.1016/j.athoracsur.2019.02.064.

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init